Author

A. Prenafeta

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 1 Organism:non-human primate· 1

Frequent Co-Authors

R. March· 3 shared A. Barreiro· 2 shared A. Fernandez· 2 shared C. Garriga· 2 shared E. Pradenas· 2 shared G. Bech-Sabat· 2 shared J. Blanco· 2 shared J. Segales· 2 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

R. March

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Fetal protection against bovine viral diarrhea virus types 1 and 2 after vaccination of the dam with the DIVENCE vaccine

E. Taberner, M. Gibert, C. Montbrau, I. Munoz, J. Mallorqui, H. Santo Tomas, A. Prenafeta, R. March

This study shows that vaccinating pregnant heifers with DIVENCE reduces fetal BVDV infection and clinical signs after challenge with BVDV-1 or BVDV-2.

bioRxiv · Apr 12, 2024 · PreprintImmunology

Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates

A. Prenafeta, G. Bech-Sabat, S. Moros, A. Barreiro, A. Fernandez, M. Canete, M. Roca, L. Gonzalez, C. Garriga, J. Confais, M. Toussenot, H. Contamin, A. Pizzorno, M. Rosa-Calatrava, E. Pradenas, , L. Ferrer

This study evaluates the PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates, showing high antibody levels, balanced cellular immunity, and reduced viral load.

bioRxiv · Dec 13, 2022Immunology

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

A. Barreiro, A. Prenafeta, G. Bech-Sabat, M. Roca, E. Perozo, R. March, L. Gonzalez-Gonzalez, L. Madrenas, J. Corominas, A. Fernandez, A. Moros, M. Molas, T. Pentinat-Pelegrin, C. Panosa, A. Moreno, , Barr

This paper evaluates a recombinant RBD fusion heterodimer vaccine in mice, showing 100% efficacy against SARS-CoV-2 variants and neutralizing antibodies.

bioRxiv · Nov 22, 2021Immunology